Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 197.14% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 11.54M.
Fairly Valued
The company’s latest PE is -11.57, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.50M shares, decreasing 4.02% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 0.00 shares of this stock.